Topics

Galapagos NV: EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

16:05 EDT 15 Aug 2019 | FinanzNachrichten

Foster City, Calif. and Mechelen, Belgium - August 15, 2019 22.01 CET - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorizat...

Original Article: Galapagos NV: EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

NEXT ARTICLE

More From BioPortfolio on "Galapagos NV: EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS"

Quick Search